Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes.
Filì C
•
Malagola M
•
Follo MY
altro
FANIN, Renato
2013